肿瘤细胞治疗研究
英文原题：ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma.
实体瘤中的嵌合抗原受体（CAR）T 细胞免疫治疗因缺乏理想靶点而受到严重限制。
实体瘤中的嵌合抗原受体（CAR）T细胞免疫疗法受到理想靶点缺乏的严重限制。在本期《Cancer Cell》中，Bergaggio等人发现，间变性淋巴瘤激酶（ALK）抑制剂可通过提高癌细胞中的靶点密度，增强ALK特异性CAR-T细胞对神经母细胞瘤的作用。
Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic lymphoma kinase (ALK) inhibitors can enhance the function of ALK-specific CAR T cells against neuroblastoma by increasing target density in cancer cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
